Company and Stock Identity

How Servier Connects to the Public Market

Company structure
Private company governed by a non-profit foundation
Market access
No current public listing was verified.
Research focus
The ownership is the first thing to understand here, because it changes the incentives. A company with no shareholders to answer to can fund slow research, and it also has no quarterly report that forces it to say how a partnership is going. So with Servier you will usually have to ask rather than read. Its own pages name three treatment areas: cancer, cardiometabolism and neurology. The Owkin agreement sits in cancer research, and the public announcement carries no figures, no payment terms and no named study.

The Servier governance page, read on 2026-10-31, says the Fondation Internationale de Recherche Servier, which it shortens to FIRS, is a non-profit governance foundation without capital. It says no person owns any stake in the group's capital, that a portion is held by French non-profit associations whose members are group companies, and that the rest is held by Servier itself. The company says it reinvests its profit to grow the business instead of paying it out. Checked on 2026-10-31.

Open the public company market data feed for the full directory, ownership relationships, stock identifiers, and dated snapshots.

First-Hand Company News

Latest Developments

... Owkin ... Company source

Owkin licenses K Pro and its MOSAIC patient data to Servier for cancer research

Owkin said on 11 September 2026 that it agreed to license K Pro, which it calls its AI Scientist, to Servier, together with multimodal patient data from the Owkin MOSAIC network, for cancer research. Owkin says Servier research teams will reach that data inside K Pro and use it to study the biology of hard to treat cancers, and that the agreement builds on earlier work the two did together on finding patient subgroups. Thomas Clozel, the Owkin co-founder and chief executive, is quoted saying that pairing K Pro with Owkin's multimodal patient data lets Servier scientists reach answers that manual analysis alone cannot deliver. Claude Bertrand, the Servier executive vice president for research and development, is quoted saying that having high quality patient data and AI driven analysis in one place helps his teams make and test ideas with more speed and confidence. The announcement carries no figures and no payment terms.

Why it matters: This is not a plain software licence, because the data comes with it. An AI research tool is only as good as what it is allowed to read, and most drug companies spend more time getting permission to use data than analysing it. Bundling the two removes that wait, and that is the real product here. The open question is how much of the MOSAIC data Servier can actually see, under what consent terms, and for how long, because none of that is in the announcement. There is also no named cancer target and no measure of success, so for now this is a research ability rather than a research result.

See company developments across the healthcare AI market.

Careers and Qualifications

What to Know Before Applying

Work areas: The careers site shows research and development roles such as organic and medicinal chemistry technician and quality control, clinical operations roles such as senior clinical operations project manager, medical representative sales roles, and support functions. It says Servier works across 41 countries with more than 20,000 people, and offers apprenticeships, internships and the French international corporate volunteer programme.

Qualification signal: A foundation owned company hires for the long run, and the tenure on its own pages shows it. That rewards people who want to finish a programme rather than move every two years. For data and AI work, the useful signal is experience with cancer research data under European privacy rules, because that is where the Owkin agreement actually lands.

Check current roles at Servier. A careers page is the source of record for openings. This profile does not claim a role is open unless the company lists it now.

Related Healthcare AI Roles

Training to Compare

Buyer Snapshot

Best-fit buyer
Research and development leaders, clinical development teams, business development staff, and investors tracking where AI partnerships lead
Primary use case
Sponsor, license, or partner on AI research, molecule design, and trial measurement in drug development
Typical deployment
Drug developer. AI arrives through a research collaboration, a licence, or a tool used inside a clinical trial.

Evidence questions

  • What stage did the agreement reach, and were any payments or milestones disclosed?
  • Which programs or molecules does the AI work actually touch?
  • Has anything from the collaboration reached a clinical endpoint rather than a press release?

Regulatory and workflow questions

  • If AI produced a measurement used in a trial, has a regulator accepted that measurement?
  • Which regulatory submissions, if any, depend on the AI work?
  • Who is responsible for the quality of an AI-generated result inside a trial record?

Data and contract questions

  • Whose data trained the model, and what did the drug company contribute?
  • Who owns a molecule or design the collaboration produces?
  • What happens to the shared data if the collaboration ends?

Evidence and Regulation

FDA Clearances on Record

No clearance is linked in this directory. That is not automatically a mark against the company. Some products support the people doing the work instead of reading a patient image or signal themselves.

First-Hand Sources